Next Article in Journal
p53 as a Dichotomous Regulator of Liver Disease: The Dose Makes the Medicine
Previous Article in Journal
Therapeutic Properties and Biological Benefits of Marine-Derived Anticancer Peptides
Open AccessArticle

CpG ODN1826 as a Promising Mucin1-Maltose-Binding Protein Vaccine Adjuvant Induced DC Maturation and Enhanced Antitumor Immunity

Department of Immunology, College of Basic Medical Science, Jilin University, Xinjiang Street 125, Changchun 130021, China
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(3), 920; https://doi.org/10.3390/ijms19030920
Received: 13 February 2018 / Revised: 13 March 2018 / Accepted: 15 March 2018 / Published: 20 March 2018
(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
Mucin 1 (MUC1), being an oncogene, is an attractive target in tumor immunotherapy. Maltose binding protein (MBP) is a potent built-in adjuvant to enhance protein immunogenicity. Thus, a recombinant MUC1 and MBP antitumor vaccine (M-M) was constructed in our laboratory. To enhance the antitumor immune activity of M-M, CpG oligodeoxynucleotides 1826 (CpG 1826), a toll-like receptor-9 agonist, was examined in this study as an adjuvant. The combination of M-M and CpG 1826 significantly inhibited MUC1-expressing B16 cell growth and prolonged the survival of tumor-bearing mice. It induced MUC1-specific antibodies and Th1 immune responses, as well as the Cytotoxic T Lymphocytes (CTL) cytotoxicity in vivo. Further studies showed that it promoted the maturation and activation of the dendritic cell (DC) and skewed towards Th1 phenotype in vitro. Thus, our study revealed that CpG 1826 is an efficient adjuvant, laying a foundation for further M-M clinical research. View Full-Text
Keywords: CpG ODN 1826; antitumor vaccine; MUC1-MBP; dendritic cells CpG ODN 1826; antitumor vaccine; MUC1-MBP; dendritic cells
Show Figures

Graphical abstract

MDPI and ACS Style

Jie, J.; Zhang, Y.; Zhou, H.; Zhai, X.; Zhang, N.; Yuan, H.; Ni, W.; Tai, G. CpG ODN1826 as a Promising Mucin1-Maltose-Binding Protein Vaccine Adjuvant Induced DC Maturation and Enhanced Antitumor Immunity. Int. J. Mol. Sci. 2018, 19, 920.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop